SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Evofem Biosciences,
Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the
PharmaVOICE 100 Most Inspiring People, an annual list of the
100 most innovative, influential and inspirational people in the
life-sciences industry.
Ms. Pelletier was recognized for her unwavering commitment to
advancing the sexual and reproductive health of women and for her
leadership role in Evofem's rapid growth and evolution.
During her tenure as CEO, she has led the Company's transition to
the public market, secured U.S. regulatory approval of Phexxi™
(lactic acid, citric acid and potassium bitartrate), the first and
only non-hormonal, prescription contraceptive gel, and raised more
than $400 million through multiple
financing rounds. The Company is also advancing EVO100 into a Phase
3 clinical trial for the prevention of urogenital transmission of
chlamydia and gonorrhea in women.
"Saundra is a visionary leader whose compassion captures your
attention, who inspires you to be more, and whose intellect changes
your worldview," said Anne
Marbarger, Executive Director at Padres Pedal the Cause.
"Under Saundra's leadership, Evofem Biosciences is bringing to
market innovative products that will fundamentally change women's
health and drive gender parity during a time in history where it is
particularly relevant."
Ms. Pelletier was diagnosed with late-stage breast cancer in
July 2018 and continued running
Evofem while undergoing multiple surgeries and intensive
chemotherapy. In addition to her roles as CEO and single mother of
a 13-year-old son, she is also active in her community through such
organizations as Padres Pedal the Cause.
"I am honored to be recognized by PharmaVoice among such
an accomplished group of individuals and am grateful to those who
nominated me," said Ms. Pelletier. "As the CEO of a female-forward
company committed to improving women's health, I am thrilled with
the breadth of female leaders and diversity of talent reflected on
this list. Together, we are innovating and advocating for new
therapies, better care and improved outcomes, while also investing
in the next generation of trailblazers, entrepreneurs and
glass-ceiling breakers."
PharmaVOICE Magazine released its annual list of the
100 most inspiring people in life sciences on August 1, identifying industry thought leaders
and innovators who have made the biggest impact in their
fields.
About Phexxi™ (lactic acid, citric acid and potassium
bitartrate) Vaginal Gel
Phexxi is a prescription vaginal gel
used to prevent pregnancy in females who choose to use an on-demand
method of birth control. Phexxi is only effective when used
immediately before (or up to one hour before) each act of
vaginal sex. It is not effective when used after vaginal
sex.
Important Safety Information
What are the possible side effects of Phexxi?
There
have been a few cases of urinary bladder infection and kidney
infection reported in clinical studies. One of the cases was
serious. Avoid Phexxi if you have had repeated urinary tract
infections or other urinary tract problems.
The most common side effects were vaginal burning,
vaginal itching, vaginal yeast infection, urinary tract infection,
vaginal area discomfort, bacterial vaginosis, and vaginal
discharge. Women also reported genital discomfort, pain while
urinating, and vaginal pain. Some male partners reported genital
discomfort.
What else should I know about using Phexxi?
Phexxi
does not protect against any sexually transmitted diseases,
including HIV. Avoid using Phexxi with a vaginal ring.
Contact your healthcare provider if you are experiencing severe
genital irritation or discomfort or urinary tract symptoms. Avoid
Phexxi if you or your sexual partner is allergic to lactic acid,
citric acid, potassium bitartrate, or any of the ingredients in
Phexxi. Stop using Phexxi if you develop an allergic reaction.
Please see full Prescribing Information for Phexxi, including
Patient Information.
Please report side effects by contacting Evofem
Biosciences® toll-free at 1-833-EVFMBIO or contact
FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
About Evofem Biosciences, Inc.
Evofem Biosciences,
Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi™ (lactic acid, citric
acid and potassium bitartrate), is the first and only hormone-free,
prescription gel approved in the United
States for the prevention of pregnancy. The Company is also
advancing EVO100 into Phase 3 clinical trials for the prevention of
urogenital transmission of both Chlamydia trachomatis
infection (chlamydia) and Neisseria gonorrhoeae infection
(gonorrhea) in women. For more information, please visit
www.evofem.com.
Forward-Looking Statements
This press release includes
"forward-looking statements," within the meaning of the safe harbor
for forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended; and the Private
Securities Litigation Reform Act of 1995, including, without
limitation, statements related to Evofem's expectations. Various
factors could cause actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Important factors that could cause actual
results to differ materially from those discussed or implied in the
forward-looking statements, or that could impair the value of
Evofem Biosciences' assets and business are disclosed in Evofem's
SEC filings, including its Annual Report on Form 10-K for the year
ended December 31, 2019 filed with the SEC on March
12, 2020, its Quarterly Report on Form 10-Q for the quarter
ended March 31, 2020 filed with the SEC on May 6,
2020 and its Current Report on Form 8-K filed with the SEC
on June 2, 2020. All forward-looking statements are expressly
qualified in their entirety by such factors. Evofem does not
undertake any duty to update any forward-looking statement except
as required by law.
Contact
Media
Cara Miller
Evofem Biosciences
cmiller@evofem.com
O: (858) 550-1900 x272
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-ceo-saundra-pelletier-named-to-pharmavoice100--the-most-inspiring-people-in-life-sciences-301104413.html
SOURCE Evofem Biosciences, Inc.